D-Pd Improves PFS vs Pd Alone in Relapsed/Refractory Multiple Myeloma
The addition of daratumumab to pomalidomide and dexamethasone improved PFS among patients with relapsed-refractory MM.
Diagnosis & Disease Information
Investigational Multiple Myeloma Treatment Gets Orphan Drug Status
CellProtect (XNK Therapeutics) is an autologous ex vivo expanded and activated NK cell-based therapy, which is produced by selective expansion and activation of NK cells from the peripheral blood of patients with cancer.
BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
New Drug Product: Blenrep
This slideshow shows drug information for Blenrep. Click here for the complete Blenrep monograph.
Daratumumab Combo Approved for Relapsed/Refractory Multiple Myeloma
The approval was based on data from the phase 3 CANDOR study and the phase 1b EQUULEUS trial.
Blenrep Approved for Relapsed/Refractory Multiple Myeloma
Blenrep is a humanized, afucosylated, IgG1 anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent, monomethyl auristatin F.
FDA Panel Votes on Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma
The FDA Oncologic Drugs Advisory Committee voted in favor (12-0) of the approval of belantamab mafodotin (GSK2857916; GlaxoSmithKline) for patients with relapsed or refractory multiple myeloma.
Subcutaneous Formulation of Daratumumab Approved for Multiple Myeloma
Darzalex Faspro is a new subcutaneous formulation that contains daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase, an endoglycosidase.
FDA Approves New Treatment Option for Multiple Myeloma
The FDA has approved Sarclisa (isatuximab-irfc; Sanofi), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
Belantamab Mafodotin Gets Priority Review for Heavily Pretreated Multiple Myeloma
The FDA has granted Priority Review to the Biologics License Application (BLA) of belantamab mafodotin (GSK2857916; GlaxoSmithKline) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
